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Introduction 
According to the WHO classification, primary lymphoma 
of the bone (PLB) is defined as a monostotic disease 
involving a single skeletal site with or without the 
involvement of the regional lymph nodes, or as a 
polyostotic disease affecting multiple skeletal sites 
without visceral or lymph node involvement.1 Primary 
lymphoma bone (PLB) is extremely rare. The diagnosis is 
based on cortical and adjacent soft tissue involvement. 
On the contrary distant visceral and lymph node 
involvement is part of PLB or not is controversial in the 
literature. PLB affects 1.7/1,000,000 people in US with 5% 
of extra nodal involvement and 3% malignancies.2,3 It is a 
tumour of lymphoid tissues as lymph nodes and spleen.4 
It presents with pain or swelling of the affected area. The 
tumour can be low grade, intermediate or high grade. 
Burkett's lymphoma is an example of a fast-growing 
tumour.4 PLB contributes to only 3% of all bone tumours 
and is usually seen in adult life. It can occur in all bones 
but predominantly in bones with marrow and most are 
large cells with B cell lineage, called diffuse large B-cell 
lymphoma (DLBCL).4,5 On plain x-ray, it can present with 
the lytic pattern, sclerotic pattern, increased density 
pattern, or near normal which makes biopsy important.4,6 
Due to the low prevalence even in countries with good 
record maintainence as the United States, the information 
on PLB is scarce. This study aimed to determine the 
experience in diagnosing and treating adult patients with 
PLB in a tertiary care hospital of Karachi. The paediatric 
population was excluded because PLB in children is 
treated as a systemic disease rather than an isolated bone 
pathology. 
Methods 
A retrospective cross sectional study was conducted on all 
patients diagnosed with PLB or treated at AKU from 2005 
to 2019. The diagnosis was based on a biopsy of the bone 
tumour. Patients were included in this study regardless of 
sex, race, age and co-morbids. Moreover, patients who 
had primary lymphoma other than bone or had received 
treatment for a Secondary Lymphoma of bone were 
excluded. 
Approval for the study was obtained from the Ethical 
Review Committee of the institution. Patients who were 
part of the study were identified using medical record 
numbers. Noted were demographics of the patients 
including their age, sex, site of tumour, Follow-up (in 
months), Co-morbids, Type of Lymphoma, Histological 
subtype of Lymphoma, size of the primary tumour, stage 
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Abstract 
Objective: To determine the experience at the Aga Khan University Hospital in diagnosing and treating adult 
patients with primary lymphoma of bone. 
Methodology: All patients with Primary lymphoma of bone (PLB) that were diagnosed and/or treated at Aga Khan 
University Hospital, Karachi from 2005 to 2019 were included as part of this study. 
Result: There were 17 patients with PLB including 13 (76.5%) males and 4 (23.5%) females with a mean age of 44 ± 
16.5 years. Nine patients were between 30-59 years of age at diagnosis. The mean follow-up time of patients was 
80±46.7 months. Six patients had tumours of pelvic bone followed by tibia (5) and femur (4). Four patients had a 
pathological fracture at the time of presentation whereas 2 (11.8%) required surgical fixation of the pathological 
fracture. The stage of the tumour was based on Ann Arbor classification. Nine (52.9%) cases had Stage 1 disease, 7 
(41.2%) had stage IV disease with metastasis in extra nodal tissues. As for treatment, every patient received 
chemotherapy whereas 5 (29.4%) received adjuvant radiotherapy. Complete remission in the size of the tumour was 
seen in 11 (64.7%) patients while 6 (35.3%) had partial remission. Post-treatment, 4 (23.5%) patients expired. The 
mean Overall Survival (OS) time was 80.18 ± 46.71months with a survival rate of 76.5% 
Conclusion: Primary lymphoma of the bone can be treated with medical regime and good prophylactic surgeries 
to avoid pathological fracture such as intramedullary nailing.  
Keywords: Lymphoma, Pelvic bone, Pathological fracture, Survival, Metastasis. (JPMA 71: S-83 [Suppl. 5]; 2021)
of cancer, involved bone, presence of extra-lymphatic 
spread, pathological fracture, modality of treatment 
including Chemotherapy, Radiotherapy, Immunotherapy 
and surgery, type of remission, number of relapses, size of 
tumour after treatment (in case of incomplete remission) 
and post-chemotherapy complications. The collected 
data was analysed using Statistical Package for Social 
Sciences v. 21 (SPSS). Means and frequency were 
calculated along with survival analysis using the Kaplan-
Meier test.  
Results 
Medical records of 17 patients with PLB were reviewed. 
There were 13 (76.5%) males and 4 (23.5%) females with a 
mean age of 44±16.5 years. Out of which 4 (23.5%) 
patients were less than 30 years of age, 9 (53%) patients 
were between 30-59 years and 4 (23.5%) were equal to or 
above 60 years of age at diagnosis. The mean follow-up 
time was 80±46.7 (8-184) months. 
Some patients had comorbids along with the tumour in 
which 2 (11.8%) patients had Diabetes Mellitus type 2 and 2 
had hypertension. Hepatitis B, Gilberts syndrome, and 
ischaemic heart disease were seen in only 1 (5.9%) case each. 
All the patients had non-Hodgkin lymphoma DLBCL type. 
Most of the patients had a tumour in the Pelvic bones 
followed by the femur, tibia, radius, and scapula (Figure-1). 
Lesion on kidneys on PET- CT was seen in 3 (17.6%) cases, 
2 (11.8%) had a lesion in the liver on PET CT, 3 (17.6%) 
presented with distant metastasis, and the remaining 9 
(52.9%) had solitary bone lesions with no skipped or 
distant lesions on PET CT. Pathological fractures were 
noted in 4 (23.5%) cases at the site of the lesion. Surgical 
fixation of the pathological fracture was required in only 2 
(11.8%) patients. 
The staging of the tumour was based on Ann Arbor 
classification7 Stage 1 disease was seen in 9 (52.9%) 
patients; 7 patients (41.2%) had stage IV disease with 
metastasis in extranodal tissues. One (5.9%) patient had 
stage II disease. As for treatment, every patient received 
chemotherapy: 16(94.1%) received RCHOP (Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine, and 
Prednisolone), 3 (17.6%) received a high dose 
(Methotrexate) MTX along with RCHOP regime, 1 (5.9%) 
was given RDHAP (Rituximab, Dexamethasone, 
cytarabine, and Cisplatin). Five (29.4%) patients returned 
with febrile neutropenia for which chemotherapy was 
stopped and treatment was given. One (5.9%) patient 
each presented with acute gastroenteritis and oral 
thrush whereas 10(58.8%) patients tolerated 
chemotherapy well. 
Five (29.4%) patients received radiotherapy. Complete 
remission in the size of the tumour was observed in 11 
(64.7%) patients with 6 (35.3%) having partial remission. 
Multiple relapses in the course of treatment were 
encountered in 4(23.5%) patients. Out of 17 patients, 4 
(23.5%) expired, making the overall survival rate of 
76.5% with a median time of 144.6 months (SEM 16.70) 
(Figure-2). 
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Figure-1: Bone tumor sites in patients of Bone lymphoma.
Figure-2: Overall survival curve of patients.
Discussion 
Primary bone lymphoma (PLB) is extremely rare presenting 
with pain and swelling on the affected area.2 The current 
study was carried out to share our experience of patients 
with PLB on their diagnosis and treatment. To our 
knowledge, this is the largest study done in the 
subcontinent (Pakistan, India, and Bangladesh) which 
discusses the patients with the disease and their prognosis. 
Even the Surveillance, Epidemiology, and End Results (SEER) 
database of the US does not include the data regarding the 
effect of chemotherapy on these patients.2 The principle to 
treat PLB is far different from sarcomas.3 In recent times 
much progress has been made to diagnose and stage the 
disease by using PET CT. This provides the anatomical and 
physiologic activities of the lesion. But still, no significant 
change in the incidence and overall survival has been noted. 
This supports the need to prospectively conduct a study at 
a multicenter and multinational level.2,5 Jacob et.al, also 
commented on the fact that appendicular tumour site is a 
predictor of survival compared to axial locations but some 
studies (which they describe in their publication) have 
different observations due to confounding factors.2 
Differential diagnoses of such lesions include Ewing's 
sarcoma and osteosarcoma.3,4 According to the literature, 
PLB occurs most commonly in the femur followed by the 
pelvis. On the contrary in Japan, pelvis is the most common 
site. PLB shows a variety of presentations on plain X-ray. The 
X-ray of a patient of our series, who presented with a lesion 
in the right sacroiliac joint, showed patchy increased density 
along the right sacroiliac joint (Figure-3). In our study also, 
most of the cases were of pelvic bone followed by tibia 
and femur. In PLB patients mostly present with pain (80-
95%), swelling in 30-40%, and pathological fracture in 10-
15%.9,10 The time between the disease onset and 
presentation to the clinic is generally short (8 months).8 
Also, lymphoma in bones can develop around prosthetic 
devices especially anaplastic large cell lymphomas (ALCL) 
which present with swelling and erythema at the surgical 
site a few years after implant surgery.10 According to the 
literature, the median age of diagnosis of PLB is 45-60 
years while our patients mean age was 44 years which is 
consistent with international data. For this reason 
patients presenting with pain or swelling should be 
advised plain X-ray to detect the lesion. In case a lesion is 
noted, MRI should be performed which is the gold 
standard for diagnosis of PLB. If PLB is in the bone with 
local extension of the lesion, PET CT is recommended for 
staging.5,8,11 In MRI more specific characteristics of PLB are 
present as compared to the plain X-ray film.6 For staging 
Ann Arbour system7 is used. Furthermore, metastatic 
workup and biopsy are done to know the nature of the 
disease and exclude other differentials, some studies 
suggest doing anchored multiplex PCR. Seven patients in 
the presented series showed metastatic disease. Bone 
tumours cannot be dealt with under the care of a single 
specialty. A multidisciplinary approach is recommended 
and at our center, such cases are discussed in Tumour 
Boards where orthopaedic oncological surgeons, medical 
and radio-oncologist specialists offer their expert opinion 
for the various treatment choices. The factors under 
consideration include age, socioeconomic factors, and 
marital status. Age is an important predictor of survival 
which could be due to the ability to endure 
chemotherapy and lesser comorbidities play a significant 
role in giving treatment options to the patients. Higher 
socioeconomic and married patients also show a better 
prognosis when compared to their counterparts.2 The first 
choice and evidence based treatment for DLBCL is 
cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) plus etoposide. This has shown 
complete remission. Immunotherapy with rituximab (R-
CHOP) is not well established in literature because most of 
the data is from the time when rituximab was not 
available in the market.4,6 Similarly, offering radiotherapy 
is controversial and can be on case based need, still 
further clinical trials are needed to prove its efficacy.8 It is 
also recommended that immunotherapy should be given 
before radiotherapy and currently R-CHOP is the first line 
treatment for PLB.11 If PLB is in a weight bearing bone 
then weight bearing limitations should be placed or the 
patient should be in protected weight bearing to prevent 
a fracture. At our institute the patients are discussed in 
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Figure-3: X-ray Pelvis of our patient showing Patchy increased density noted along the 
right sacroiliac joint.
tumour boards and the board decides on case need basis 
that whether patient needs radiotherapy or not. On the 
contrary, in a study patients with advanced-stage disease, 
who were treated with chemotherapy plus radiotherapy, 
had a poorer outcome compared with those who were 
treated with chemotherapy alone. Post treatment once 
remission is achieved, strict follow-up is required. 
Literature has reported a local relapse of 7-10% and 17-
22% of distant metastasis.11  
Conclusion 
This study proves that PLB can be treated without any 
surgical intervention. Primary lymphoma of bone can be 
treated with good medical management. Prophylactic 
surgery is done to avoid pathological fracture for example 
intramedullary nailing in the femur. In this situation 
surgical morbidity can be avoided by early diagnosis and 
a multidisciplinary approach. Chemotherapy and if 
needed radiotherapy is applied. 
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